NCT07036809

Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 90 (actual)
• Sponsor: Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

The goal of this observational study is to evaluate the levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients with Acute Leukemia (Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)). The main questions it aims to answer are: What are the levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients with Acute Lymphoblastic Leukemia? What are the levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients with Acute Myeloid Leukemia? Researchers will compare patients with Acute Leukemia (30 with ALL and 30 with AML) to 30 healthy control subjects to see if there are significant differences in the levels of Antithrombin III, Protein C, Protein S, and D-dimer. Participants will: Undergo full history and clinical examination. Have routine hematological analysis including Complete Blood Count (CBC), blood film, Erythrocyte sedimentation rate (ESR), Prothrombin Time Test and INR (PT/INR), and partial thromboplastin time (PTT). Have specific tests for quantitative measurement of Antithrombin III, Protein C, Protein S, and D-dimer. Undergo Flow cytometry immunophenotyping.

Conditions

• Acute Leukemia

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Antithrombin III	quantitative measurement(%)
DIAGNOSTIC_TEST	Protein C	quantitative measurement(%)
DIAGNOSTIC_TEST	Protein S	quantitative measurement(%)
DIAGNOSTIC_TEST	D-dimer	quantitative measurement( ug/ml)
DIAGNOSTIC_TEST	Flow cytometry immunophenotyping	Flow cytometry immunophenotyping

Timeline

• Start date: 2023-06-01
• Primary completion: 2025-10-01
• Completion: 2025-10-01
• First posted: 2025-06-25
• Last updated: 2026-01-29

Locations

1 site across 1 country: Egypt